Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire August 01, 2025 CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on August 1, 2025, it awarded an inducement grant to five new employees […]

NEW YORK, NY / ACCESS Newswire / August 1, 2025 / If you suffered a loss on your Lockheed Martin Corporation (NYSE:LMT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/lockheed-martin-corporation-lawsuit-submission-form?prid=159192&wire=1&utm_campaign=8 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / August 1, 2025 / If you suffered a loss on your Replimune Group, Inc. (NASDAQ:REPL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/replimune-group-inc-lawsuit-submission-form?prid=159191&wire=1&utm_campaign=4 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

Spectral Capital Corporation (OTC:FCCN), a leading developer and acquirer of cutting-edge AI and quantum technologies, announced today that it has developed over 100 innovations in hybrid computing in 2025 alone within its broader portfolio of more than 500 patentable inventions in process. These advancements focus specifically on Hybrid Quantum-Classical Algorithms-one of the most promising and

NEW YORK, NY / ACCESS Newswire / August 1, 2025 / If you suffered a loss on your 3D Systems Corporation (NYSE:DDD) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/3d-systems-corporation-lawsuit-submission-form?prid=159202&wire=1&utm_campaign=14 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / August 1, 2025 / If you suffered a loss on your Neogen Corporation (NASDAQ:NEOG) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neogen-corporation-lawsuit-submission-form?prid=159199&wire=1&utm_campaign=8 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

NEW YORK, NY / ACCESS Newswire / August 1, 2025 / If you suffered a loss on your Petco Health and Wellness Company, Inc. (NASDAQ:WOOF) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/petco-lawsuit-submission-form?prid=159190&wire=1&utm_campaign=24 or contact Joseph E. Levi, Esq. via email

NEW YORK, NY / ACCESS Newswire / August 1, 2025 / If you suffered a loss on your PepGen Inc. (NASDAQ:PEPG) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pepgen-inc-lawsuit-submission-form?prid=159189&wire=1&utm_campaign=19 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

NEW YORK, NY / ACCESS Newswire / August 1, 2025 / If you suffered a loss on your RxSight, Inc. (NASDAQ:RXST) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/rxsight-inc-lawsuit-submission-form?prid=159198&wire=1&utm_campaign=23 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

NEW YORK, NY / ACCESS Newswire / August 1, 2025 / If you suffered a loss on your Sarepta Therapeutics, Inc. (NASDAQ:SRPT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sarepta-lawsuit-submission-form?prid=159197&wire=1&utm_campaign=9 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or